Devyser Diagnostics AB (publ) (STO:DVYSR)

Market Cap	2.42B
Revenue (ttm)	235.10M
Net Income (ttm)	-45.70M
Shares Out	16.59M
EPS (ttm)	-2.76
PE Ratio	n/a
Forward PE	92.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,905
Average Volume	22,925
Open	149.20
Previous Close	149.60
Day's Range	145.00 - 149.40
52-Week Range	83.30 - 155.00
Beta	0.78
RSI	54.75
Earnings Date	Jul 22, 2025

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analys...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 121
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2024, Devyser Diagnostics AB's revenue was 216.90 million, an increase of 28.12% compared to the previous year's 169.30 million. Losses were -61.50 million, 14.7% more than in 2023.